News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

04 November 2011 National Jewish Health Names Recipient of The CSL Behring – National Jewish Health Fellowship in Immunology

National Jewish Health (NJH) announced that Jordan Abbott, M.D., is the recipient of the CSL Behring – National Jewish Health Fellowship in Immunology for 2011.

> Read More
06 October 2011 CSL Behring Named Life Sciences Company Of The Year By Philadelphia Business Journal and Pennsylvania Bio

CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27 countries, has been named Life Sciences Company of the Year by Philadelphia Business Journal and Pennsylvania Bio. The King of Prussia-based business is a subsidiary of CSL Limited (ASX:CSL).

> Read More
03 October 2011 Young People With Rare Medical Conditions
Faced With Care Issues and Possible
Healthcare Cuts Make Their Voices Heard

Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and cities from where they hail, places like San Antonio, Pittsburgh, Des Moines and New York.

> Read More
14 September 2011 Plasma Protein Therapies Month Raises Awareness of Rare Diseases And The Importance of Donating Plasma

Every year thousands of people in the United States who suffer with rare and serious disorders such as hemophilia, hereditary angioedema, von Willebrand disease, primary immune deficiencies and inherited respiratory disease receive lifesaving therapies derived from human plasma. These conditions affect people of all ages from children to the elderly, and from all ethnic, racial and socioeconomic backgrounds.

> Read More
06 September 2011 CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research into Neuroimmunology

To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards. Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.

> Read More
Page 26 of 51 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+